163 related articles for article (PubMed ID: 36736921)
1. Neighborhood Deprivation and Rurality Associated With Patient-Reported Outcomes and Survival in Men With Prostate Cancer in NRG Oncology RTOG 0415.
Bai J; Pugh SL; Eldridge R; Yeager KA; Zhang Q; Lee WR; Shah AB; Dayes IS; D'Souza DP; Michalski JM; Efstathiou JA; Longo JM; Pisansky TM; Maier JM; Faria SL; Desai AB; Seaward SA; Sandler HM; Cooley ME; Bruner DW
Int J Radiat Oncol Biol Phys; 2023 May; 116(1):39-49. PubMed ID: 36736921
[TBL] [Abstract][Full Text] [Related]
2. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P
Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373
[TBL] [Abstract][Full Text] [Related]
3. Influence of deprivation and rurality on patient-reported outcomes of men living with and beyond prostate cancer diagnosis in the UK: A population-based study.
Smith L; Downing A; Norman P; Wright P; Hounsome L; Watson E; Wagland R; Selby P; Kind P; Donnelly DW; Butcher H; Huws D; McNair E; Gavin A; Glaser AW
Cancer Epidemiol; 2020 Dec; 69():101830. PubMed ID: 33002843
[TBL] [Abstract][Full Text] [Related]
4. Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer.
Lukka HR; Pugh SL; Bruner DW; Bahary JP; Lawton CAF; Efstathiou JA; Kudchadker RJ; Ponsky LE; Seaward SA; Dayes IS; Gopaul DD; Michalski JM; Delouya G; Kaplan ID; Horwitz EM; Roach M; Pinover WH; Beyer DC; Amanie JO; Sandler HM; Kachnic LA
Int J Radiat Oncol Biol Phys; 2018 Oct; 102(2):287-295. PubMed ID: 29913254
[TBL] [Abstract][Full Text] [Related]
5. Quality of Life in Patients With Low-Risk Prostate Cancer Treated With Hypofractionated vs Conventional Radiotherapy: A Phase 3 Randomized Clinical Trial.
Bruner DW; Pugh SL; Lee WR; Hall WA; Dignam JJ; Low D; Swanson GP; Shah AB; Malone S; Michalski JM; Dayes IS; Seaward SA; Nguyen PL; Pisansky TM; Chen Y; Sandler HM; Movsas B
JAMA Oncol; 2019 May; 5(5):664-670. PubMed ID: 30763425
[TBL] [Abstract][Full Text] [Related]
6. Five-Year Patient-Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer.
Lukka HR; Deshmukh S; Bruner DW; Bahary JP; Lawton CAF; Efstathiou JA; Kudchadker RJ; Ponsky LE; Seaward SA; Dayes IS; Gopaul DD; Michalski JM; Delouya G; Kaplan ID; Horwitz EM; Roach M; Feng FY; Pugh SL; Sandler HM; Kachnic LA
Int J Radiat Oncol Biol Phys; 2023 Jul; 116(4):770-778. PubMed ID: 36592721
[TBL] [Abstract][Full Text] [Related]
7. Impact of Hypofractionated Radiotherapy on Patient-reported Outcomes in Prostate Cancer: Results up to 5 yr in the CHHiP trial (CRUK/06/016).
Staffurth JN; Haviland JS; Wilkins A; Syndikus I; Khoo V; Bloomfield D; Parker C; Logue J; Scrase C; Birtle A; Malik Z; Panades M; Eswar C; Graham J; Russell M; Ferguson C; O'Sullivan JM; Cruickshank CA; Dearnaley D; Hall E;
Eur Urol Oncol; 2021 Dec; 4(6):980-992. PubMed ID: 34489210
[TBL] [Abstract][Full Text] [Related]
8. What is the Impact of Social Deprivation on Physical and Mental Health in Orthopaedic Patients?
Wright MA; Adelani M; Dy C; OʼKeefe R; Calfee RP
Clin Orthop Relat Res; 2019 Aug; 477(8):1825-1835. PubMed ID: 31107333
[TBL] [Abstract][Full Text] [Related]
9. Association of Neighborhood Deprivation With Prostate Cancer and Immune Markers in African American and European American Men.
Pichardo MS; Minas TZ; Pichardo CM; Bailey-Whyte M; Tang W; Dorsey TH; Wooten W; Ryan BM; Loffredo CA; Ambs S
JAMA Netw Open; 2023 Jan; 6(1):e2251745. PubMed ID: 36662526
[TBL] [Abstract][Full Text] [Related]
10. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.
Fransson P; Nilsson P; Gunnlaugsson A; Beckman L; Tavelin B; Norman D; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Zackrisson B; Kjellén E; Franzén L; Widmark A
Lancet Oncol; 2021 Feb; 22(2):235-245. PubMed ID: 33444529
[TBL] [Abstract][Full Text] [Related]
11. Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial.
Spratt DE; Liu VYT; Michalski J; Davicioni E; Berlin A; Simko JP; Efstathiou JA; Tran PT; Sandler HM; Hall WA; Thompson DJS; Parliament MB; Dayes IS; Correa RJM; Robertson JM; Gore EM; Doncals DE; Vigneault E; Souhami L; Karrison TG; Feng FY
Int J Radiat Oncol Biol Phys; 2023 Oct; 117(2):370-377. PubMed ID: 37137444
[TBL] [Abstract][Full Text] [Related]
12. Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial.
Michalski JM; Moughan J; Purdy J; Bosch W; Bruner DW; Bahary JP; Lau H; Duclos M; Parliament M; Morton G; Hamstra D; Seider M; Lock MI; Patel M; Gay H; Vigneault E; Winter K; Sandler H
JAMA Oncol; 2018 Jun; 4(6):e180039. PubMed ID: 29543933
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Patient-Reported Outcomes From a Phase 3 Randomized Prospective Trial of Conventional Versus Hypofractionated Radiation Therapy for Localized Prostate Cancer.
Shaikh T; Li T; Handorf EA; Johnson ME; Wang LS; Hallman MA; Greenberg RE; Price RA; Uzzo RG; Ma C; Chen D; Geynisman DM; Pollack A; Horwitz EM
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(4):722-731. PubMed ID: 28244407
[TBL] [Abstract][Full Text] [Related]
14. Did the Physical and Mental Health of Orthopaedic Patients Change After the Onset of the COVID-19 Pandemic?
Hollenberg AM; Yanik EL; Hannon CP; Calfee RP; O'Keefe RJ
Clin Orthop Relat Res; 2023 May; 481(5):935-944. PubMed ID: 36696142
[TBL] [Abstract][Full Text] [Related]
15. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
Aluwini S; Pos F; Schimmel E; Krol S; van der Toorn PP; de Jager H; Alemayehu WG; Heemsbergen W; Heijmen B; Incrocci L
Lancet Oncol; 2016 Apr; 17(4):464-474. PubMed ID: 26968359
[TBL] [Abstract][Full Text] [Related]
16. Hypofractionation for clinically localized prostate cancer.
Hickey BE; James ML; Daly T; Soh FY; Jeffery M
Cochrane Database Syst Rev; 2019 Sep; 9(9):CD011462. PubMed ID: 31476800
[TBL] [Abstract][Full Text] [Related]
17. Quality of life in men living with advanced and localised prostate cancer in the UK: a population-based study.
Downing A; Wright P; Hounsome L; Selby P; Wilding S; Watson E; Wagland R; Kind P; Donnelly DW; Butcher H; Catto JWF; Cross W; Mason M; Sharp L; Weller D; Velikova G; McCaughan E; Mottram R; Allen M; Kearney T; McSorley O; Huws DW; Brewster DH; McNair E; Gavin A; Glaser AW
Lancet Oncol; 2019 Mar; 20(3):436-447. PubMed ID: 30713036
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Patient-reported Outcomes After External Beam Radiation Therapy and Combined External Beam With Low-dose-rate Brachytherapy Boost in Men With Localized Prostate Cancer.
Lee DJ; Barocas DA; Zhao Z; Huang LC; Resnick MJ; Koyoma T; Conwill R; McCollum D; Cooperberg MR; Goodman M; Greenfield S; Hamilton AS; Hashibe M; Kaplan SH; Paddock LE; Stroup AM; Wu XC; Penson DF; Hoffman KE
Int J Radiat Oncol Biol Phys; 2018 Sep; 102(1):116-126. PubMed ID: 30102188
[TBL] [Abstract][Full Text] [Related]
19. Effect of Long-Term Hormonal Therapy (vs Short-Term Hormonal Therapy): A Secondary Analysis of Intermediate-Risk Prostate Cancer Patients Treated on NRG Oncology RTOG 9202.
Mirhadi AJ; Zhang Q; Hanks GE; Lepor H; Grignon DJ; Peters CA; Rosenthal SA; Zeitzer K; Radwan JS; Lawton C; Parliament MB; Reznik RS; Sandler HM
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):511-515. PubMed ID: 28126300
[TBL] [Abstract][Full Text] [Related]
20. Moderate Hypofractionation in Intermediate- and High-Risk, Localized Prostate Cancer: Health-Related Quality of Life From the Randomized, Phase 3 HYPRO Trial.
Wortel RC; Oomen-de Hoop E; Heemsbergen WD; Pos FJ; Incrocci L
Int J Radiat Oncol Biol Phys; 2019 Mar; 103(4):823-833. PubMed ID: 30458234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
